Type 2 Diabetes
Details
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and progressive beta-cell failure, resulting in chronic hyperglycemia. It is the most common form of diabetes (>90% of cases) and is strongly linked to obesity, physical inactivity, and genetic predisposition. T2DM confers markedly elevated cardiovascular risk — ASCVD is the leading cause of morbidity and mortality — and is commonly accompanied by hypertension (the most common comorbidity), dyslipidemia, and chronic kidney disease.
Key Facts
Cardiovascular Risk in T2DM
- Hypertension is the most common comorbidity in T2DM and the most modifiable CVD risk factor; it amplifies stroke, MI, HF, and CKD risk synergistically with hyperglycemia (sources/bp-dm-bproad-nejm-2025, rating: very high)
- GLP-1 receptor agonists (oral semaglutide — SOUL trial NEJM 2025) reduce 3-point MACE (HR 0.86; 95% CI 0.77–0.96; P=0.006), driven primarily by nonfatal MI reduction
Blood Pressure Targets in T2DM
- BPROAD trial (NEJM 2025; n=12,821 Chinese T2DM patients ≥50 years): Intensive treatment (SBP <120 mmHg) vs standard (SBP <140 mmHg) — primary composite (nonfatal stroke/MI, HF hosp, CV death) HR 0.79 (95% CI 0.69–0.90; P<0.001); stroke HR 0.79; albuminuria HR 0.87; serious AEs equivalent; hypotension 0.1% vs <0.1%; hyperkalemia 2.8% vs 2.0% (sources/bp-dm-bproad-nejm-2025, rating: very high)
- Current guidelines (ACC/AHA 2017, ADA 2024, ESH 2023, ESC 2024): SBP <130 mmHg; AHA 2025 encourages <120 mmHg if tolerated (COR 2b) — BPROAD provides first RCT evidence supporting this
- ACEi/ARB preferred if eGFR <60 or albuminuria ≥30 mg/g (COR 1, AHA 2025)
- See concepts/Blood-Pressure-Target-T2DM for full trial evidence and guideline context
Contradictions / Open Questions
- BP target <120 vs <130 mmHg: BPROAD now supports <120 mmHg as superior to <140 mmHg; whether <120 mmHg is superior to <130 mmHg specifically has not been tested in a head-to-head RCT. (sources/bp-dm-bproad-nejm-2025, rating: very high)
- ACCORD vs BPROAD: ACCORD (2010) failed to show benefit of intensive BP control — now explained by underpowering and factorial glucose confound; BPROAD definitively contradicts ACCORD's null conclusion.
Connections
- Related to entities/Hypertension — most common T2DM comorbidity; BP target data now RCT-supported
- Related to concepts/Blood-Pressure-Target-T2DM — central concept for BP management in T2DM
- Related to entities/MASLD — MASLD/NAFLD highly prevalent in T2DM
- Related to entities/Obesity — major T2DM driver; shared metabolic pathway